ClinicalTrials.gg
RecruitingNCT07154667Updated Dec 29, 2025

Evaluation of the Auryzon™ EAR 2.0 System in Ear Reconstruction

An interventional study of Use of AuryzoN™ EAR 2.0 device and Hand carving in Microtia, Congenital, Microtia and Microtia-Anotia, sponsored by Nemours Children's Clinic. Recruiting at 1 site in United States. Open to participants aged 5 Years to 20 Years. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Nemours Children's Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
5 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Congenital Microtia with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Congenital Microtia · United States.

Started
2025
with 1 other
No phase
4 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Nemours Children's Clinic

Among the 11 studies in Congenital Microtia with a site in United States, this one is one of 2 that started in 2025, is one of 4 with no phase, and was the 11th registered.

Congenital Microtia

33 studies on the registry are indexed under Congenital Microtia; 10 are open to participants now.

Browse Congenital Microtia studies →

Open to participants now

3 of the 11 studies in Congenital Microtia with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Congenital Microtia studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 5 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Congenital Microtia with a site in United States, or all of them as a file.
02

Study summary

This study aims to improve surgical outcomes for children and young adults with ear differences severe secondary to congenital conditions (like microtia, a condition where the ear is underdeveloped), trauma (such as dog bites), or surgical resections secondary to skin cancer. The investigators have developed a novel medical device to shape cartilage into pre-determined shapes that, once assembled, assists the surgeon in creating an anatomically accurate cartilaginous ear framework, reduce surgery time, and minimize wire need. Other factors that might affect the quality of surgical outcomes will be examined in clinical trial participants.

Read the detailed description

Cartilage-based ear reconstruction addresses congenital anomalies, such as microtia, as well as deformities due to trauma or oncologic resection by replacing like with like tissue. Current technique involves the use of the autologous cartilage as the gold standard and involves harvesting patient's own rib cartilage and carving them into different ear subunits, which are then assembled with numerous steel wires. Challenges of this technique include high operator-dependency due to extensive carving, inconsistent outcomes, prolonged anesthesia, and need for wire or suture fixation, leading to wire extrusion, cartilage resorption, and overall high cost. The previously published prototype device utilized specialized blades to standardize this process. Given the complexity of auricular reconstruction and the suboptimal outcomes by most plastic surgeons globally, there is a pressing need for a standardized, enhanced and accessible method for an accurate ear framework.

If successful, this project has the potential to improve plastic surgeons' technical proficiency in producing anatomically accurate auricular frameworks. Achieving these aims could substantially advance reconstructive clinical techniques in clinical practice and broaden access to satisfactory ear reconstruction beyond the limited number of highly specialized centers. Furthermore, the novel blade design has the potential to reduce the need for wire suturing, while also reducing overall framework production time, anesthesia duration, and costs.

Comparing hand-carved and blade-cut techniques for cadaveric cartilage, the study will enhance understanding of potential differences in resorption rate between these methods. This study aims to: 1. Promote framework production through precise bladecutting, facilitating the construction of cartilaginous ear frameworks while improving outcomes and reducing operative time and costs; 2. Standardize framework production independently of operator skill. 3. Reduce the number of wires required for construct fixation, further contributing to decreased operative time and cost; 4. Minimize the risk of wire extrusion by limiting wires usage during framework production through the novel blade design. 5. Compare differences in framework appearance, stability, time to production, operative time, intraoperative morbidity, and construct resorption within the first year postoperatively when using cadaveric cartilage.

03

Conditions studied

  • Microtia, Congenital
  • Microtia
  • Microtia-Anotia
  • Ear Deformities, Acquired
  • Ear Deformity External
  • Ear Malformation
  • Ear Cartilage

Browse trials for

Keywords

  • microtia
  • ear reconstruction
  • craniofacial difference
  • anotia
  • plastic surgery
  • ear defect
  • ear trauma
  • ear deficit
04

Who can participate

Ages eligible
5 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 5-20 years seeking to undergo surgical ear reconstruction or microtia repair under general anesthesia through NCH-FL
  • Pre-existing physical deformity of the ear necessitating surgical reconstruction
  • Patient of sufficient health to undergo surgery under general anesthesia
  • Parental or legally acceptable representative (LAR) permission obtained for inclusion in the study; patient assent obtained where age-appropriate
  • Sufficient fluency in English or Spanish to complete patient/parent surveys

Exclusion criteria

Exclusion Criteria:

  • Patients who will be ≤4 years old, or ≥21 years old at time of surgery
  • Patients with ear deformities do not require surgical correction
  • Patient's whose ear reconstruction surgery will be performed somewhere other than Nemours Children's Hospital - Florida
  • Patients determined to be in poor health to undergo surgery under general anesthesia
  • Parental or LAR permission cannot be obtained, and/or patient of sufficient age and cognitive capacity declines to assent
  • Lack of fluency in English or Spanish to complete patient/parent surveys
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    AuryzoN™ EAR 2.0 arm

    Participants in the AuryzoN™ EAR 2.0 arm will receive ear reconstruction surgery using the AuryzoN™ EAR 2.0 device

    Procedure: Use of AuryzoN™ EAR 2.0 device

  • Active comparator
    Hand Carved

    Participants in this arm will receive ear reconstruction surgery using the hand carved technique

    Procedure: Hand carving

Interventions

  • ProcedureUse of AuryzoN™ EAR 2.0 device

    AuryzoN™ EAR 2.0 is an investigational non-significant risk device developed to improve cartilage construct shape and stability prior to use in ear reconstructive surgery.

  • ProcedureHand carving

    Standard hand carving using standard surgical blades will be performed in this intervention arm of the study.

06

What researchers measure

Primary outcomes

  1. Evaluate the results of patient and parent satisfaction with the constructed ear's shape and appearance and compare the results between the hand-carved cohort and the AuryzoN™ EAR 2.0 cohort using a four-question survey.

    Parents and patients (over age 12) will complete a four-question survey asking how much they like: the shape of the new ear, how the new ear looks, how natural the new ear looks, and the new ear overall. Participants will respond to each question with a rating from 1-5, with 1 being "do not like it at all" and 5 being "like it very much". Investigators will compare the responses from the hand-carved cohort and the AuryzoN™ EAR 2.0 cohort to determine which has more favorable outcomes.

    Time frame: From the beginning of the study to the end at 5 years

  2. Evaluating reduction in operative time between the two techniques.

    Compare changes in operative time between participants enrolled in the AuryzoN™ EAR 2.0 arm and the traditional hand-carving arm.

    Time frame: From the beginning of the study to the end at 5 years

  3. Evaluating reduction in assembly time between the two techniques.

    Compare the assembly time of cartilage into the ear construct between the AuryzoN™ EAR 2.0 arm and the hand-carving technique.

    Time frame: From the beginning of the study to the end at 5 years

  4. Evaluating reduction in wire usage between the two techniques

    Compare the amount of wire required for assembly of the ear construct between the Auryzon™ EAR 2.0 arm and the hand-carving technique.

    Time frame: From the beginning of the study to the end at 5 years

  5. Evaluation of cartilage stability

    Assess cartilage framework stability over 12 months post-surgically using photography, measurements, 3D imaging, and histopathological analysis.

    Time frame: From the beginning of the study to the end at 5 years

  6. Evaluation of resorption rates

    Assess resorption rates over 12 months post-surgically using photography, measurements, 3D imaging and histopathological analysis.

    Time frame: From the beginning of the study to the end at 5 years

Secondary outcomes

  1. Conduct histopathological analysis assessing outcomes of banked allogeneic cartilage between stage 1 and stage 2 surgeries

    Cartilage will be banked in participants' groin or supraclavicular region during the six months between stage 1 and stage 2 ear reconstruction surgeries. Investigators will conduct histopathological analysis to assess the quality of the banked cartilage when it is recovered for use in the stage 2 surgery. This pathological analysis of the banked cartilage will be performed by using Hematoxylin \& Eosin (H\&E) staining and evaluating chondrocytes and extracellular matrix for signs of inflammatory response or rejection.

    Time frame: From the beginning of the study to the end at 5 years

  2. Assessing any changes to the dimensions of the banked cartilage when it is retrieved for stage 2 reconstruction surgery.

    Surgeons will measure the dimensions of the cartilage before banking at the end of the stage 1 surgery and after retrieving the banked cartilage during the stage 2 surgery. Investigators will compare the dimensions of the cartilage before and after banking to determine whether there are any signing or warping or resorption

    Time frame: From the beginning of the study to the end at 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Nagata S. A new method of total reconstruction of the auricle for microtia. Plast Reconstr Surg. 1993 Aug;92(2):187-201. doi: 10.1097/00006534-199308000-00001. PubMed 8337267 ↗
  • Tanzer RC. Microtia--a long-term follow-up of 44 reconstructed auricles. Plast Reconstr Surg. 1978 Feb;61(2):161-6. doi: 10.1097/00006534-197802000-00001. PubMed 622405 ↗
  • Su-Genyk P, Quatela O, Quatela V. Our Evolution of Approaches to Microtia Reconstruction. Facial Plast Surg Clin North Am. 2024 Feb;32(1):105-125. doi: 10.1016/j.fsc.2023.09.002. PubMed 37981407 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2030, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Sep 4, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07154667
Responsible party
Angelo Leto barone (Craniofacial and Pediatric Plastic Surgeon, Nemours Children's Clinic) — Principal investigator
First posted
Sep 4, 2025
Start date
Oct 1, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Dec 29, 2025

Study contacts

Heaven Sippio - Executive Assistant
Contact
heaven.sippio@nemours.org
407-650-7358
Ishpriya Sharma - Research Project Specialist, PhD
Contact
ishpriya.sharma@nemours.org
Angelo A Leto Barone, MD
principal investigator · Nemours Children's Hospital, Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion